Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.

You may also be interested in...



Testing Part B Payment Cuts: Sequester Means Providers Get ASP+4%

Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?

Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs

A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.

Medicare Payments For Hospital Outpatient Drugs Set At ASP+6% For 2013

CMS issues its final 2013 hospital outpatient prospective payment system rule for Medicare Part B. The ASP+6% payment rate for drugs is aimed at producing more predictable reimbursement for separately billable drugs, biologics and radiopharmaceuticals.

Topics

UsernamePublicRestriction

Register

PS075153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel